Aurora Cannabis
Market Cap
CA$4.9b
Last Updated
2019/10/22 00:43 UTC
Data Sources
Company Financials +
Executive Summary
Aurora Cannabis Inc. produces and distributes medical cannabis products.
Snowflake
Fundamentals
High growth potential and fair value.
Similar Companies
Share Price & News
How has Aurora Cannabis's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-3.4%
ACB
-1.3%
CA Pharmaceuticals
0.2%
CA Market
1 Year Return
-52.4%
ACB
-49.1%
CA Pharmaceuticals
2.4%
CA Market
Return vs Industry: ACB underperformed the Canadian Pharmaceuticals industry which returned -49.1% over the past year.
Return vs Market: ACB underperformed the Canadian Market which returned 2.4% over the past year.
Shareholder returns
| ACB | Industry | Market | |
|---|---|---|---|
| 7 Day | -3.4% | -1.3% | 0.2% |
| 30 Day | -28.0% | -21.1% | -3.3% |
| 90 Day | -44.1% | -32.6% | -1.8% |
| 1 Year | -52.4%-52.4% | -49.1%-49.1% | 6.0%2.4% |
| 3 Year | 121.4%113.3% | 86.3%84.9% | 14.2%4.0% |
| 5 Year | n/a | 288.2%288.2% | 27.2%8.6% |
Price Volatility Vs. Market
How volatile is Aurora Cannabis's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Does The Aurora Cannabis Inc. (TSE:ACB) Share Price Fall With The Market?3 weeks ago | Simply Wall St
The Aurora Cannabis (TSE:ACB) Share Price Has Soared 362%, Delighting Many Shareholders1 month ago | Simply Wall St
Do Institutions Own Aurora Cannabis Inc. (TSE:ACB) Shares?Valuation
Is Aurora Cannabis undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ACB (CA$4.8) is trading below our estimate of fair value (CA$9.68)
Significantly Below Fair Value: ACB is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ACB is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: ACB is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ACB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ACB is good value based on its PB Ratio (1.1x) compared to the CA Pharmaceuticals industry average (1.8x).
Next Steps
Future Growth
How is Aurora Cannabis forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?
73.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ACB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: ACB is forecast to become profitable over the next 3 year, which is considered above average market growth.
High Growth Earnings: ACB's loss is forecast to worsen by 0% next year.
Revenue vs Market: ACB's revenue (35.1% per year) is forecast to grow faster than the Canadian market (5.5% per year).
High Growth Revenue: ACB's revenue (35.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ACB's Return on Equity is forecast to be low in 3 years time (4.3%).
Next Steps
Past Performance
How has Aurora Cannabis performed over the past 5 years?
-44.3%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: ACB is unprofitable, and losses have increased over the past 5 years at a rate of -44.3% per year.
Accelerating Growth: Unable to compare ACB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.6%).
Return on Equity
High ROE: ACB has a negative Return on Equity (-6.79%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: ACB is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: ACB is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is Aurora Cannabis's financial position?
Financial Position Analysis
Short Term Liabilities: ACB's short term assets (CA$664.2M) exceeds its short term liabilities (CA$436.4M)
Long Term Liabilities: ACB's short term assets (664.2M) do not cover its long term liabilities (676.4M)
Debt to Equity History and Analysis
Debt Level: ACB's debt to equity ratio (14.7%) is considered satisfactory
Reducing Debt: ACB's debt to equity ratio has reduced from 105% to 14.7% over the past 5 years.
Balance Sheet
Inventory Level: ACB has a low level of unsold assets or inventory.
Debt Coverage by Assets: ACB's debt is covered by short term assets (assets are 1.031510x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ACB has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ACB has less than a year of cash runway if free cash flow continues to reduce at historical rates of -105.5% each year
Next Steps
Dividend
What is Aurora Cannabis's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate ACB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ACB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if ACB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ACB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ACB's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
What is the CEO of Aurora Cannabis's salary, the management and board of directors tenure and is there insider trading?
1.9yrs
Average management tenure
CEO
Terry Booth (54yo)
4.8yrs
Tenure
CA$2,408,656
Compensation
Mr. Terry Booth founded Aurora Cannabis Inc. in 2013 and has been its Chief Executive Officer since December 9, 2014. Mr. Booth had served as Chief Executive Officer and Director at Australis Capital Inc. Â ...
CEO Compensation Analysis
Compensation vs. Market: Terry's total compensation ($USD1.84M) is about average for companies of similar size in the Canadian market ($USD2.95M).
Compensation vs Earnings: Terry's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
1.9yrs
Average Tenure
54yo
Average Age
Experienced Management: ACB's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Age and Tenure
3.5yrs
Average Tenure
54yo
Average Age
Experienced Board: ACB's board of directors are considered experienced (3.5 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 8,320 |
| Max Price | CA$12.05 |
| Entity | Individual |
| Role | Member of the Board of Directors Founder |
| Shares | 800,000 |
| Max Price | CA$10.10 |
| Entity | Individual |
| Role | Senior Key Executive Chief Commercial Officer |
| Shares | 20,000 |
| Max Price | CA$12.00 |
Ownership Breakdown
Management Team
Allan Cleiren
Chief Operating Officer
- Tenure: 2.4yrs
- Compensation: CA$1.10m
Michael Singer (54yo)
Executive Chairman of the Board
- Tenure: 2.9yrs
- Compensation: CA$2.20m
Terry Booth (54yo)
Founder
- Tenure: 4.8yrs
- Compensation: CA$2.41m
Steve Dobler (54yo)
Founder
- Tenure: 4.8yrs
- Compensation: CA$1.33m
Glen Ibbott
Chief Financial Officer
- Tenure: 2.4yrs
- Compensation: CA$1.32m
Darren Karasiuk (47yo)
Chief Commercial Officer
- Tenure: 1.1yrs
- Compensation: CA$1.86m
Darryl Vleeming
Chief Information Officer
- Tenure: 1.9yrs
Jillian Swainson
Chief Legal Officer & Corporate Secretary
- Tenure: 1.8yrs
Jonathan Page (50yo)
Chief Science Officer
- Tenure: 0.9yrs
Ananth Krishnan
Vice President of Capital Markets & Investor Relations
- Tenure: 0yrs
Board Members
Margaret Atkins (62yo)
Independent Director
- Tenure: 0.7yrs
- Compensation: CA$199.21k
Ronald Funk (63yo)
Lead Independent Director
- Tenure: 0.7yrs
- Compensation: CA$230.01k
Adam Szweras (47yo)
Independent Director
- Tenure: 4.2yrs
- Compensation: CA$246.76k
Michael Singer (54yo)
Executive Chairman of the Board
- Tenure: 2.9yrs
- Compensation: CA$2.20m
Terry Booth (54yo)
Founder
- Tenure: 4.8yrs
- Compensation: CA$2.41m
Jason Ronald Dyck (51yo)
Independent Director
- Tenure: 4.6yrs
- Compensation: CA$294.01k
Steve Dobler (54yo)
Founder
- Tenure: 4.8yrs
- Compensation: CA$1.33m
Norma Beauchamp (58yo)
Independent Director
- Tenure: 1.3yrs
- Compensation: CA$243.68k
Company Information
Aurora Cannabis Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Aurora Cannabis Inc.
- Ticker: ACB
- Exchange: TSX
- Founded:
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$4.938b
- Shares outstanding: 1.03b
- Website: https://auroramj.com
Number of Employees
Location
- Aurora Cannabis Inc.
- 10355 Jasper Avenue
- Suite 500
- Edmonton
- Alberta
- T5J 1Y6
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 21P | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Dec 2014 |
| ACB | NYSE (New York Stock Exchange) | Yes | Common Shares | US | USD | Dec 2014 |
| ACB | TSX (The Toronto Stock Exchange) | Yes | Common Shares | CA | CAD | Dec 2014 |
| 0UJG | LSE (London Stock Exchange) | Yes | Common Shares | GB | CAD | Dec 2014 |
Biography
Aurora Cannabis Inc. produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, including facility eng ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/22 00:43 |
| End of Day Share Price | 2019/10/21 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.